Forte Biosciences, Inc.
FBRXUnited States
43 filed reports · 369 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
43 reports · Mar 2017 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 5 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 29 | 2,860 | Mar 2017 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 9 | 2,346 | Dec 2017 to Dec 2025 |
| Current · 8-KSEC EDGAR | 3 | 5 | Jun 2018 to Sep 2019 |
| Annual · 10-K/ASEC EDGAR | 2 | 2 | Dec 2022 to Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 12, 2026 | 256 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 11, 2026 | 140 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 31, 2026 | 427 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 14, 2025 | 161 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 14, 2025 | 93 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 15, 2025 | 86 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 28, 2025 | 247 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 14, 2024 | 109 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 14, 2024 | 87 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 13, 2024 | 85 | Open |
| FY2023 | 10-K/A | Dec 31, 2023 | Apr 29, 2024 | 1 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 18, 2024 | 191 | Open |
Financial data
369 concepts · 5,213 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial368 concepts · 5,208 facts · Dec 2015 to Jun 2026
- Prepaid insurance57 · Dec 2019 to Jun 2026
- Cash and cash equivalents at carrying value54 · Dec 2015 to Jun 2026
- Allocated share based compensation expense53 · Dec 2015 to Jun 2026
- General and administrative expense (US GAAP)53 · Dec 2015 to Jun 2026
- Increase decrease in accounts payable53 · Dec 2015 to Jun 2026
- Increase decrease in accrued liabilities53 · Dec 2015 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets53 · Dec 2015 to Jun 2026
- Net income loss53 · Dec 2015 to Jun 2026
- Operating expenses (US GAAP)53 · Dec 2015 to Jun 2026
- Operating income loss53 · Dec 2015 to Jun 2026
- Share based compensation53 · Dec 2015 to Jun 2026
- Stockholders equity (US GAAP)51 · Dec 2015 to Jun 2026
- Accounts payable current49 · Dec 2016 to Jun 2026
- Accrued liabilities current49 · Dec 2016 to Jun 2026
- Accrued professional fees current49 · Dec 2016 to Jun 2026
- Additional paid in capital common stock49 · Dec 2016 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value49 · Dec 2015 to Jun 2026
- Assets49 · Dec 2016 to Jun 2026
- Assets current49 · Dec 2016 to Jun 2026
- Common stock par or stated value per share49 · Dec 2016 to Jun 2026
- Common stock shares authorized49 · Dec 2016 to Jun 2026
- Common stock shares issued49 · Dec 2016 to Jun 2026
- Common stock shares outstanding49 · Dec 2016 to Jun 2026
- Common stock value49 · Dec 2016 to Jun 2026
Guidance1 concepts · 5 facts · Aug 2018 to Nov 2019
- Free Cash Flow Guidance5 · Aug 2018 to Nov 2019
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.